Sanofi (ADR) (SNY)
Develops immunology-focused medicines and vaccines across a broad international footprint.
Something off on this page? Send us feedback.
Develops prescription medicines and vaccines across immunology, rare diseases, neurology and oncology, with Dupixent and vaccines central to current execution. Consumer health now sits outside operational control, leaving a single Biopharma segment whose international business depends on clinical development, regulatory approval, manufacturing quality and product safety.
Develops and markets prescription medicines and vaccines across immunology, rare diseases, neurology, oncology and other treatments. A broad international footprint is coordinated from Paris, while these activities are reported within a single Biopharma operating segment.
Specialty-care execution centers on expanding Dupixent across immune-mediated diseases, supported by biotechnology and rare-disease capabilities added through Genzyme. Vaccine growth and research productivity sit alongside launch execution as operating priorities.
Consumer health now sits outside operational control after the Opella separation, sharpening the focus on medicines and vaccines. Results depend on clinical development, regulatory approvals, manufacturing quality and product safety, while the Nasdaq-listed ADS represents half of one Paris-listed ordinary share.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | RBC Capital | Initiate | Rating: — | |
| Jul 8, 2026 | Morgan Stanley | Target | Target: $52 | Target: $49 |
| May 1, 2026 | Morgan Stanley | Downgrade | Target: $56 | Target: $52 |
| Apr 20, 2026 | BNP Paribas | Target | Target: — | Target: $50 |
| Apr 20, 2026 | Exane BNP Paribas | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.27B · Total debt $27.01B · Total assets $147.85B · Shareholders' equity $79.28B
- Revenue
- $14.09B
- Operating income
- $2.73B
- Net income
- $392.9M
Reported in EUR, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 7.78% | 189.85M ADS | |
|---|---|---|---|
| 739 holders · as of Jun 30, 2026 | |||
| Insiders | 5.04% | 123.01M ADS | |
| 1 holder · as of Apr 10, 2026 | |||
| Other | 87.18% | 2.13B ADS | |
| remainder | |||
2.44B ADS (1 ADS = 1 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
AmundiInsider | 5.04% | 123.01M | filed Apr 10, 2026 |
Dodge & CoxInstitution | 1.15% | 28.09M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.44% | 10.70M ADS | as of Jun 30, 2026 |
Fisher Asset Management, LLCInstitution | 0.44% | 10.63M ADS | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 0.33% | 8.01M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- GSK (ADR)
Competes across vaccines and respiratory biologics
- AbbVie
Direct rival to Dupixent in systemic atopic dermatitis
- AstraZeneca (ADR)
UK biopharma rival in severe-asthma biologics
- Merck
Direct challenger to Beyfortus in infant RSV prevention
- Eli Lilly
US rival in atopic-dermatitis biologics and basal insulin
- Pfizer
Competes in infant RSV prevention and hemophilia prophylaxis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sanofi (ADR) | $42.03 | −1.11% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| GSK (ADR) | $50.26 | −1.61% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| AbbVie | $262.15 | −0.88% | $467.37B | 74.5 | 17.2 | 7.3 | +10.2% |
| AstraZeneca (ADR) | $166.74 | −0.81% | $260.70B | 25.2 | 15.7 | 4.2 | +6.4% |
| Merck | $148.10 | −0.94% | $369.24B | 119.6 | 17.2 | 5.6 | +5.1% |
| Eli Lilly | $1,140.28 | −2.11% | $1.10T | 39.1 | 27.9 | 13.8 | +47.7% |
| Pfizer | $27.50 | −0.87% | $158.10B | 36.7 | 9.8 | 2.5 | +2.6% |
| Median | 37.9 | 16.4 | 4.9 | +5.9% |